Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Watch SpaceX launch 119 payloads to orbit from California early on March 30 - 2Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- 3$30K Disability Scam Implodes After Surf Trip in Mexico
- 4Denny's is shutting down restaurants around the country. What's behind the closures?
- 5Independence from the rat race for Recent college grads: Systems and Tips
- Can a mammogram help identify heart disease?
- 5 Morning Schedules That Stimulate Your Day
- Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Eight arrested in joint Scotland and Spain gang raids
- The Appearance of Experience: Embracing the Reduced Portage Horse
- Top Breakfast Food: What's Your Morning Enjoyment?
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Fake new headlights rule steer Australian drivers astray
- Astronauts beam home Christmas wishes from International Space Station: 'I think we may be orbiting a little higher than Santa' (video)
